mIcroRNA sequencing of LINC01929 KD knockdown and control samples in MCF7 and MDA-MB-231 breast cancer cell lines

LncRNA LINC01929 was knocked down using anti-LINC01929 antisense oligonucleotides (ASOs) in the ER+ breast cancer cell line MCF7 and the triple-negative breast cancer cell line MDA-MB-231. Overall design: To investigate the impact of lncRNA LINC01929 on the microRNA levels of ER+ and triple-negative breast cancer, small RNA-sequencing was conducted on MCF7 and MDA-MB-231 cell lines. Cells were treated with either control ASO or anti-LINC01929 ASO for 48 hours. Following the ASO treatment, small RNA was extracted with mirVana™ miRNA Isolation Kit (Invitrogen, Thermo Fisher Scientific) as per manufacturer's instructions. Total RNA from same lysates was used to confirm knockdown of LINC01929 using qPCR as described. Samples were sent to TCAG for Illumina NovaSeq - SP flowcell.